Table 5 Uni- and multivariate Cox regression analyses for overall survival (validation set)

Age at diagnosis

>60 vs. ≤ 60

325

1.22 (0.88–1.70)

0.234

Sex

Male vs. female

328

1.08 (0.80–1.45)

0.633

AJCC Stage

2 vs. 1

478

2.01 (1.32–3.07)

4.71 × 10^–3*

408

1.57 (0.88–2.82)

0.128

3 vs. 1

3.11 (1.33–7.23)

408

2.21 (0.82–5.97)

0.119

4 vs. 1

2.85 (1.16–7.05)

408

1.44 (0.19–10.97)

0.723

Pathological type

Other vs. ductal

510

0.36 (0.09–1.45)

0.151

Pathological grade

2 vs. 1

242

1.52 (0.65– 3.55)

0.185

3 vs. 1

2.15 (0.91– 5.11)

4 vs. 1

2.66 (0.53–13.3)

Pathological tumor size (pT)

2 vs. 1

364

1.49 (0.62–3.59)

0.131

3 vs. 1

1.95 (0.86–4.42)

4 vs. 1

2.93 (1.01–8.48)

Pathological lymph node status (pN)

1 vs. 0

414

1.83 (1.34–2.48)

1.24 × 10^–4*

408

1.50 (1.04–2.16)

2.95 × 10^–2*

Collisson subtypes

Exocrine-like vs. classical

562

1.00 (0.77–1.29)

2.32 × 10^–3*

562

0.94 (0.66–1.34)

0.732

Quasi-mesenchymal vs. classical

1.52 (1.17–1.99)

562

1.15 (0.83–1.59)

0.395

Moffitt subtypes, ‘type’

Classical vs. basal-like

562

0.64 (0.51–0.80)

6.29 × 10^–5*

562

1.00 (0.72–1.38)

0.994

Bailey subtypes

Immunogenic vs. ADEX

562

0.81 (0.57–1.17)

8.98 × 10^–6*

562

0.68 (0.43–1.06)

0.090

Pancreatic progenitor vs. ADEX

0.97 (0.70–1.35)

562

0.79 (0.51–1.23)

0.302

Squamous vs. ADEX

1.64 (1.22–2.19)

562

1.09 (0.68–1.74)

0.731

25-gene classifier

STS-like vs. LTS-like

562

1.93 (1.55–2.42)

7.47 × 10^–9*

408

2.04 (1.54–2.70)

6.33 × 10^–7*

562

1.77 (1.38–2.26)

6.33 × 10^–6*